Transdermal Fluorescence Monitoring for CRRT Medicament Clearance

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Patients undergoing continuous renal replacement therapy (CRRT) face challenges in accurately determining the clearance rate of medicaments from their bloodstream, which is crucial for optimizing dosing prescriptions, due to the lack of standard tests and the variability in CRRT settings and filter types, leading to difficulties in managing acute kidney injury and ensuring effective drug levels.

Innovation Solution

A method involving the administration of a fluorescent agent, which is exposed to visible or infrared light to emit spectral energy, allowing for transcutaneous monitoring of its clearance rate, enabling the calculation of medicament clearance rates and adjustment of dosing prescriptions based on real-time concentration levels.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If conventional 24-hour urine collection procedure is used to measure GFR, then measurement accuracy is improved, but treatment timing is delayed and kidney function may be lost

Engineering Contradiction:

ImproveGFR measurement accuracyVSAvoidtreatment timing

Core Design Contradiction:

Measurement precisionVSLoss of time

Solution Approach 1:

The patent replaces the mechanical/physical urine collection and analysis system with an optical detection system. A fluorescent probe is administered to the patient, and its clearance is monitored using fluorescence spectroscopy through the skin, eliminating the need for urine collection and providing rapid GFR measurement without time loss.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The patent introduces a fluorescent probe as an intermediary substance to indirectly measure GFR. The probe is administered systemically, and its clearance rate serves as a surrogate marker for renal function, allowing non-invasive monitoring of GFR through transdermal fluorescence detection.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If CRRT is performed to treat AKI, then kidney function support is improved, but medicament clearance becomes unpredictable

Engineering Contradiction:

Improvekidney function supportVSAvoidmedicament clearance rate

Core Design Contradiction:

ReliabilityVSMeasurement precision

Solution Approach 1:

The patent uses a fluorescent probe that mimics the pharmacokinetic properties of medicaments to create a predictive model. By measuring the clearance rate of the fluorescent probe through transdermal fluorescence monitoring, the system predicts medicament clearance rates, allowing accurate dosing adjustments during CRRT without direct medicament measurement.

Inventive Principle:

Principle #26Copying

Solution Approach 2:

The patent implements a feedback mechanism where transdermal fluorescence monitoring continuously tracks probe clearance, and this information feeds back to adjust medicament dosing prescriptions in real-time, ensuring predictable and controlled medicament levels despite CRRT treatment.

Inventive Principle:

Principle #23Feedback

3Adaptability or versatility

If different CRRT settings and filter types are used, then treatment adaptability is improved, but medicament clearance prediction becomes difficult

Engineering Contradiction:

ImproveCRRT treatment flexibilityVSAvoidclearance rate determination

Core Design Contradiction:

Adaptability or versatilityVSDevice complexity

Solution Approach 1:

The patent systematically evaluates how different CRRT parameters (blood flow rate, filtration fraction, filter type) affect fluorescent probe clearance. By establishing mathematical relationships between these parameters and clearance rates, the system can predict medicament clearance across various CRRT configurations without increasing operational complexity.

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach enables precise monitoring and adjustment of medicament levels in patients undergoing CRRT, improving therapeutic efficacy by ensuring accurate and timely dosing, thereby enhancing patient care and treatment outcomes.

Implementation Method 1

exposing the fluorescent agent to visible or infrared light, thereby causing spectral energy to emanate from the fluorescent agent

Methodology Applied

Scientific EffectFluorescence: Fluorescence

Data Source

PatentUS12102432B2Uses of transdermal glomerular filtration rate measurement in continuous renal replacement therapy

Publication Date: 2024.10.01 MEDIBEACON INC

AI summary

Disclosed herein is a method for determining a dosing prescription for a medicament in a patient undergoing CRRT. The method generally includes administering to the bloodstream of the patient a fluorescent agent; administering to the patient at least one dose of the medicament; performing CRRT on the patient after administering the fluorescent agent to the patient; exposing the fluorescent agent to visible or infrared light; monitoring transcutaneously a change in the spectral energy from the fluorescent agent over a period of time; correlating a change in intensity of the spectral energy from the fluorescent agent to a clearance rate of the fluorescent agent from the bloodstream in the patient; calculating a clearance rate of the medicament in the patient; determining an amount of the medicament in the bloodstream of the patient as a function of time; and adjusting a dosing prescription of the medicament to the patient.